Malignancy contraindication for Regranex

Following a review by the European Medicines Agency, product information for the diabetic ulcer treatment becaplermin (Regranex) has been updated to include malignancy as a general contraindication.

The gel was previously contraindicated only in patients with skin cancer close to the application site.

In a retrospective study, patients who used three or more tubes of becaplermin had a 5.2 times greater risk of dying from cancer than matched controls, although their overall incidence of cancer was not increased.

View Regranex drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more